Key result
Gemfibrozil lipid-lowering efficacy remains independent of apolipoprotein B and AI/CIII polymorphisms.
Why the study?
Apolipoprotein B XbaI and apolipoprotein AI/CIII SstI polymorphisms have been associated with variations in serum lipoprotein levels, but their role in modulating response to gemfibrozil treatment was unclear.
Do apolipoprotein B and AI/CIII gene polymorphisms determine the lipid-modulating action of gemfibrozil in male subjects with hyperlipidemia?
Observational (n=221)
Do apolipoprotein B and AI/CIII gene polymorphisms determine the lipid-modulating action of gemfibrozil in male subjects with hyperlipidemia?
Common polymorphisms of apolipoprotein B and AI/CIII genes influence baseline serum lipid levels but do not determine the hypolipidemic response to gemfibrozil.
Answers are grounded in this paper and cite their sources.
Apolipoprotein polymorphisms may influence gemfibrozil response; leaves open whether genotyping should guide therapy in hyperlipidemia.
Apolipoprotein B XbaI polymorphism and apolipoprotein AI/CIII SstI polymorphism have been found to be associated with variations in serum lipoprotein levels. We investigated whether these gene polymorphisms are involved in determining the lipid-modulating action of gemfibrozil. Of the 221 male subjects with hyperlipidemia studied, 121 responded well to the treatment with more than a 25% reduction in the non-high-density lipoprotein cholesterol level, whereas 100 were nonresponders. Among responders, but not nonresponders, homozygosity for the apolipoprotein B X2 allele (XbaI site present) and heterozygosity for the apolipoprotein AI/CIII S2 allele (SstI site present) were associated with elevated baseline serum low-density lipoprotein cholesterol and triglyceride levels, respectively. However, the hypolipidemic effect of gemfibrozil among the responders was independent of these gene polymorphisms. These data indicate that common polymorphisms of the apolipoprotein B and apolipoprotein AI/CIII gene loci influence serum lipid levels by mechanisms that are amenable to an intervention with gemfibrozil.
No takes yet. Share an insight, caveat, or question.
Aalto‐Setälä et al. (1991) conducted an observational in Hyperlipidemia (n=221). Apolipoprotein B XbaI and apolipoprotein AI/CIII SstI polymorphisms vs. Absence of these polymorphisms was evaluated on Response to gemfibrozil treatment (>25% reduction in non-high-density lipoprotein cholesterol level). The hypolipidemic effect of gemfibrozil was independent of apolipoprotein B XbaI and apolipoprotein AI/CIII SstI polymorphisms, although they influenced baseline serum lipid levels.
Synapse has enriched 10 related papers. Consider them for comparative context: